Epirubicin HCl
(Synonyms: 盐酸表柔比星; 4'-Epidoxorubicin hydrochloride) 目录号 : GC10686An anthracycline antitumor antibiotic
Cas No.:56390-09-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
-
Purity > 98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
- NMR
Cell experiment: | Hep G2 cells (500 cells/well, monolayer) are plated in a 96-well plate. The next day the cells are treated with Epirubicin in the medium. At the end of the incubation periods, 15% volume of MTT dye solution is added. After 1 hr of incubation at 37°C, an equal volume of solubilization/stop solution (dimethylsul-foxide) is added to each well for an additional 1 hr incubation. The absorbance of the reaction solution at 570 nm is recorded. |
References: [1]. Cersosimo RJ, et al. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425-39. |
Epirubicin is an inhibitor of DNA topoisomerase (TOPII) [1].
Epirubicin belongs to the Anthracylines chemical class, it is a sort of DNA topoisomerase poison. It can inhibit the religation step of DNA topology, resulting in stabilization of the 5’ phosphotyrosyl-DNA complex (cleavage complex). These lesions are cytotoxic and lead to activation of the DNA damage response and potentially apoptosis. Because of this, it is usually used in cancer therapy. Unfortunately, it also has genotoxic side effects, including the formation of leukemogenic chromosome translocations [1].
Epirubicin is one of the chemotherapeutic agents used for the treatment of Osteosarcoma. It exhibits growth inhibition of tumors by inducing apoptosis. Conversely, it reduces apoptosis in OS cells by activating NF-κB. It is reported that epirubicin combined with cerulenin can enhance the anti-tumor activity in vitro and in vivo [2].
References:
[1] Ian G. Cowell, Caroline A. Austin. Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents. International Journal of Environmental Research and Public Health. 2012 (9): 2075-2091.
[2] Z.L. LIU, G. WANG, Y. SHU, P.A. ZOU, Y. ZHOU and Q.S. YIN. Enhanced antitumor activity of epirubicin combined with cerulenin in osteosarcoma. Molecular Medicine Reports. 2012 (5): 326-330.
Cas No. | 56390-09-1 | SDF | |
别名 | 盐酸表柔比星; 4'-Epidoxorubicin hydrochloride | ||
化学名 | (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride | ||
Canonical SMILES | CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O.Cl | ||
分子式 | C27H29NO11.HCl | 分子量 | 579.98 |
溶解度 | ≥ 55.6 mg/mL in DMSO, ≥ 10.12 mg/mL in EtOH with ultrasonic and warming, ≥ 40.33 mg/mL in Water with gentle warming | 储存条件 | 4°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.7242 mL | 8.621 mL | 17.242 mL |
5 mM | 0.3448 mL | 1.7242 mL | 3.4484 mL |
10 mM | 0.1724 mL | 0.8621 mL | 1.7242 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。